Additional Information

Chris Chien received his PhD in Tumor Biology from Georgetown University examining the role of transcription factors and their role in breast cancer. He joined the Pediatric Oncology Branch as a postdoctoral fellow studying Thymic Stromal Lymphopoietin Receptor (TSLPR) and the role it plays in resistance to chemotherapy in acute lymphoblastic leukemia (ALL). During this time, he also developed a novel chimeric antigen receptor (CAR) targeting FMS-like tyrosine kinase 3 (FLT3) receptor to target both ALL and acute myeloid leukemia (AML). His current work is helping to translate CAR T cell therapies against various targets in ALL and AML from bench to bedside.